PD-L1 IHC in NSCLC with a global and methodological perspective

被引：32
|
作者：
Thunnissen, Erik [1 ]
de langen, Adrianus J. [2 ]
Smit, Egbert F. [2 ,3 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Thorac Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
来源：
LUNG CANCER | 2017年 / 113卷
关键词：
PD-L1; Immunohistochemistry; Validation; Lung cancer; Pathology; Review; LUNG; EXPRESSION; PEMBROLIZUMAB; SPECIMENS; NIVOLUMAB; DOCETAXEL;
D O I：
10.1016/j.lungcan.2017.09.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In summary, the PD-L1 biomarker discussed here highlights the importance of understanding the practice of IHC. This can be used to the patients advantage, with appropriate usage. The currently available literature on PD-L1 IHC from a methodologic point of view has not shown that different assays are comparable. The route of laboratory developed test and commercial test validation is the same: challenging and complex. Executing this process along proper methodologic lines is needed to ensure that patients receive the most accurate and representative test outcomes.
引用
收藏
页码：102 / 105
页数：4
相关论文
共 50 条
  • [31] Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
    Niemeijer, A.
    Smit, E.
    Van Dongen, G.
    Windhorst, A. D.
    Huisman, M.
    Hendrikse, N.
    Bahce, I.
    Lueng, D.
    Smith, R.
    Hayes, W.
    Wilson, L.
    Bonacorsi, S.
    Donnelly, D.
    Morin, P.
    Poot, A.
    Vugts, D.
    Thunnissen, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1817 - S1817
  • [32] PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
    Jorgensen, Jan Trost
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
  • [33] Ezrin regulates the progression of NSCLC by YAP and PD-L1
    Bu, Fan
    Zhang, Yeping
    Zhao, Ning
    Tian, Xiaoai
    Xu, Yirong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (07): : 2239 - 2249
  • [34] Ezrin regulates the progression of NSCLC by YAP and PD-L1
    Fan Bu
    Yeping Zhang
    Ning Zhao
    Xiaoai Tian
    Yirong Xu
    Clinical and Translational Oncology, 2023, 25 : 2239 - 2249
  • [35] Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
    Bassanelli, Maria
    Sioletic, Stefano
    Martini, Maurizio
    Giacinti, Silvana
    Viterbo, Antonella
    Staddon, Anita
    Liberati, Fabrizio
    Ceribelli, Anna
    ANTICANCER RESEARCH, 2018, 38 (07) : 3789 - 3796
  • [36] The interaction of PD-L1, TMB, and genomic alterations in NSCLC
    Goldberg, Michael E.
    Gay, Laurie M.
    Fabrizio, David
    Frampton, Garrett M.
    Elvin, Julia A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Stephens, Philip J.
    Albacker, Lee A.
    CANCER RESEARCH, 2017, 77
  • [37] Clinicopathologic values of PD-L1 expression and polymorphism in NSCLC
    Kim, K. -H.
    VIRCHOWS ARCHIV, 2017, 471 : S110 - S111
  • [38] PD-L1 as a biomarker in NSCLC: challenges and future directions
    Mathew, Matthen
    Safyan, Rachael A.
    Shu, Catherine A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (18)
  • [39] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [40] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    MODERN PATHOLOGY, 2018, 31 : 755 - 755
12345